Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Title:
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Author:
Heaney, Liam G Busby, John Hanratty, Catherine E Djukanovic, Ratko Woodcock, Ashley Walker, Samantha M Hardman, Timothy C Arron, Joseph R Choy, David F Bradding, Peter Brightling, Christopher E Chaudhuri, Rekha Cowan, Douglas C Mansur, Adel H Fowler, Stephen J Niven, Robert M Howarth, Peter H Lordan, James L Menzies-Gow, Andrew Harrison, Tim W Robinson, Douglas S Holweg, Cecile T J Matthews, John G Pavord, Ian D
Appeared in:
Lancet respiratory medicine
Paging:
Volume 9 () nr. 1 pages 57-68
Year:
2021
Contents:
Publisher:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license